|
Immunogen
|
FI-MCMV
|
ELISA titer (2n) of IgG antibodyb
|
Spleen virus titers (log10PFU/ml)
|
Salivary gland virus titers (log10PFU/ml)
|
|---|
|
Dosage (μg)
|
Immunization once
|
Immunization twice
|
|---|
|
Adjuvant-free
|
0.25
|
3.33 ± 0.58
|
5.67 ± 0.52
|
5.16 ± 0.22
|
Not donef
|
|
+ Chitosan
| |
5.83 ± 1.17c
|
9.83 ± 1.17c
|
5.12 ± 0.28e
|
Not done
|
|
+ Alum
| |
6.67 ± 1.63c
|
11.17 ± 0.98c
|
5.06 ± 0.21e
|
Not done
|
|
+ MF59
| |
7.50 ± 1.52c
|
12.83 ± 1.47c,d
|
4.06 ± 0.62c,d,e
|
4.76 ± 0.48
|
|
Adjuvant-free
|
1
|
5.33 ± 0.58
|
9.17 ± 0.98
|
5.03 ± 0.40e
|
Not done
|
|
+ Chitosan
| |
6.67 ± 1.15
|
12.67 ± 1.03c
|
4.83 ± 0.12e
|
5.46 ± 0.57
|
|
+ Alum
| |
7.83 ± 0.98c
|
14.00 ± 0.63c
|
4.31 ± 0.83e
|
5.12 ± 0.91
|
|
+ MF59
| |
11.33 ± 0.82c,d
|
15.33 ± 1.03c,d
|
3.45 ± 0.56c,e
|
4.34 ± 0.42
|
|
Adjuvant-free
|
4
|
8.67 ± 0.82
|
11.67 ± 1.03
|
4.85 ± 0.21e
|
5.70 ± 0.38
|
|
+ Chitosan
| |
10.50 ± 0.55c
|
14.83 ± 1.17c
|
3.95 ± 0.48c,e
|
4.57 ± 0.74c
|
|
+ Alum
| |
11.00 ± 0.89c
|
15.17 ± 0.41c
|
3.61 ± 0.66c,e
|
4.10 ± 0.27c
|
|
+ MF59
| |
12.17 ± 0.75c
|
17.00 ± 1.10c,d
|
2.08 ± 0.81c,d,e
|
2.31 ± 0.43c,d
|
|
Chitosan only
|
-
|
Undetected
|
Undetected
|
5.76 ± 0.29
|
Not done
|
|
Alum only
| |
Undetected
|
Undetected
|
5.83 ± 0.38
|
Not done
|
|
MF59 only
| |
Undetected
|
Undetected
|
5.74 ± 0.18
|
Not done
|
|
Mock
| |
Undetected
|
Undetected
|
5.61 ± 0.36
|
Not done
|
|
PBS
| |
-
|
-
|
5.94 ± 0.25
|
Not done
|
-
aThe mice were immunized by i.p. injection twice (3 weeks apart) with various doses of vaccine (0.25, 1, or 4 μg) with or without adjuvant (MF59, alum, or chitosan). Serum samples from immunized mice were obtained 3 weeks after the first and second immunization, respectively. Mice were challenged with a lethal dose of SG-MCMV 3 weeks after the boost. Spleen virus titers 5 days later and salivary gland virus titers 3 weeks after the challenge were measured. Results are expressed as means ± standard deviation of tested mice in each group.
-
bSerum samples were diluted by two-fold serial dilutions and “n” represents the dilution factor.
-
cSignificant difference (p < 0.05), compared with the corresponding adjuvant-free subjects.
-
dSignificant difference (p < 0.05), compared with the corresponding alum adjuvant subjects.
-
eSignificant difference (p < 0.05), compared with control subjects.
-
fViral titer measurement was not performed because of the mouse death before the day 21 post-infection.
